Genechem Inc. has created conjugates comprising gemcitabine covalently linked to sialyllactose through a linker and reported to be useful for the treatment of cancer.
Medipol Ueniversitesi Zonguldak Buelent Ecevit University has patented new specific arylidene barbiturate derivatives reported to be useful for the treatment of cancer.
Shanghai Wennai Pharmaceutical Technology Co. Ltd. has described new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of breast and prostate cancer.
Vidac Pharma Holdings plc has released the results of preclinical studies with VDA-1275 in multiple mouse cancer and human cellular organoid models of solid tumors.
Dren Bio Inc. has entered into a strategic collaboration with Novartis Pharma AG which will focus on the discovery and development of therapeutic bispecific antibodies for cancer leveraging Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform.
Iaso Biotechnology Co. Ltd. has announced that China’s National Medical Products Administration (NMPA) has approved the IND application for IASO-782 injection for a new indication – systemic lupus erythematosus.
Zyversa Therapeutics Inc. has selected obesity and its related metabolic complications as the lead indication for its inflammasome ASC inhibitor IC-100.
Arrhythmogenic cardiomyopathy (ACM) is a severe genetic cardiac disorder caused by mutations in some desmosomal genes. The most frequently affected gene in patients with ACM is PKP2, the loss of which provokes desmosomal instability that leads to activation of downstream disease processes ultimately resulting in life-threatening ventricular arrhythmia and heart failure.
Integrase strand transfer inhibitors (INSTI) under a once-daily oral schedule are the standard-of-care treatment for HIV. Longer-acting oral and injectable formulations to facilitate adherence to treatment regimens are needed.
RSS
